Prime Minister Jeong Holds 27th Thursday Dialogue... Exploring Expansion Plans for Advanced Regenerative Medicine
[Asia Economy Reporter Moon Chaeseok] Prime Minister Chung Sye-kyun held the 27th Thursday Dialogue on the afternoon of the 3rd at the Prime Minister's Official Residence in Samcheong-dong, Seoul, together with experts in advanced regenerative medicine, the Prime Minister's Office announced.
This Thursday Dialogue was a follow-up to the one held just before the enforcement of the Advanced Regenerative Bio Act on July 12, discussing measures to ensure that patients can safely receive advanced regenerative medical treatment at the appropriate time.
Professor Park Sora of Inha University College of Medicine, who gave the presentation, proposed specific measures including ▲expanding clinical research on rare and intractable diseases and establishing a public fund to support treatment costs for low-income groups ▲allowing limited procedures for technologies proven to be safe ▲linking clinical research with the drug development process.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- Is This the Peak? As Others Hesitate..."The Answer Is Clear for Surviving the KOSPI 10,000 Era"
- Former Journalist and Investor Released on Bail After Gaining 11.2 Billion Won by Inflating Stock Prices Through News Articles
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
Prime Minister Chung instructed the Ministry of Health and Welfare to actively consider allowing limited medical procedures for technologies with low risk and confirmed safety based on clinical research results.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
